Q4 2023 · 13F-HR/A
Sofinnova Investments, Inc.holdings as filed
Filed 2024-08-15 · accession 0001104659-24-090054
$1.79B
Reported value
62
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 48576A100 | — | Karuna Therapeutics Inc | $437.1M | 24.5% | 1,381,149 | Common | SOLE |
| 75525N107 | — | RayzeBio Inc | $150.4M | 8.41% | 2,419,528 | Common | SOLE |
| 632307104 | NTRA | Natera Inc | $97.1M | 5.43% | 1,550,280 | Common | SOLE |
| 04351P101 | ASNDUSD | Ascendis Pharma A/S | $95.0M | 5.31% | 754,032 | Common | SOLE |
| 58933Y105 | MRK | Merck & Co Inc | $93.5M | 5.23% | 857,971 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics Inc | $85.1M | 4.76% | 3,758,686 | Common | SOLE |
| 046353108 | AZNN | AstraZeneca PLC | $57.3M | 3.20% | 850,577 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics Inc | $53.3M | 2.98% | 3,467,156 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences Inc | $51.9M | 2.90% | 1,458,881 | Common | SOLE |
| 45253H101 | IMGNEUR | ImmunoGen Inc | $45.9M | 2.57% | 1,546,902 | Common | SOLE |
| 46120E602 | ISRG | Intuitive Surgical Inc | $42.8M | 2.40% | 126,959 | Common | SOLE |
| 532457108 | LLY | Eli Lilly & Co | $37.6M | 2.10% | 64,525 | Common | SOLE |
| 23282W605 | CYTK | Cytokinetics Inc | $34.6M | 1.93% | 414,207 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics Inc | $33.5M | 1.87% | 844,008 | Common | SOLE |
| 23257D103 | CBAYUSD | CymaBay Therapeutics Inc | $33.3M | 1.87% | 1,411,769 | Common | SOLE |
| N44445109 | IMTX | Immatics NV | $31.3M | 1.75% | 2,969,039 | Common | SOLE |
| 80105N105 | SNY | Sanofi | $29.8M | 1.67% | 598,978 | Common | SOLE |
| 45720L107 | INBXUSD | Inhibrx Inc | $29.4M | 1.64% | 772,957 | Common | SOLE |
| 49177J102 | KVUE | Kenvue Inc | $26.0M | 1.45% | 1,206,939 | Common | SOLE |
| 50127T109 | KURA | Kura Oncology Inc | $24.0M | 1.34% | 1,667,321 | Common | SOLE |
| 87164F105 | SNDX | Syndax Pharmaceuticals Inc | $23.2M | 1.30% | 1,075,786 | Common | SOLE |
| 56854Q200 | MRNS* | Marinus Pharmaceuticals Inc | $19.3M | 1.08% | 1,772,699 | Common | SOLE |
| 863667101 | SYK | Stryker Corporation | $18.8M | 1.05% | 62,788 | Common | SOLE |
| 45337C102 | INCY | Incyte Corp | $18.6M | 1.04% | 296,569 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $18.6M | 1.04% | 8,814,497 | Common | SOLE |
| 45790W108 | — | Inozyme Pharma Inc | $18.2M | 1.02% | 4,280,308 | Common | SOLE |
| 28414H103 | ELAN | Elanco Animal Health Inc | $17.8M | 1.00% | 1,193,885 | Common | SOLE |
| 04016X101 | ARGX | argenx SE | $17.0M | 0.95% | 44,721 | Common | SOLE |
| 984241109 | YMABUSD | Y-mAbs Therapeutics Inc | $15.0M | 0.84% | 2,194,278 | Common | SOLE |
| N69605108 | PHVS | Pharvaris N V | $14.3M | 0.80% | 510,441 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $13.5M | 0.75% | 1,013,505 | Common | SOLE |
| 00847G705 | AGENEUR | Agenus Inc | $13.0M | 0.73% | 15,656,234 | Common | SOLE |
| 805111101 | SVRA | Savara Inc | $11.2M | 0.63% | 2,382,835 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals Inc | $10.4M | 0.58% | 352,397 | Common | SOLE |
| 12674W109 | CABA | Cabaletta Bio Inc | $9.7M | 0.55% | 429,395 | Common | SOLE |
| 45258J102 | IMVT | Immunovant Inc | $9.4M | 0.52% | 222,553 | Common | SOLE |
| 101137107 | BSX | Boston Scientific Corp | $7.6M | 0.42% | 131,000 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc | $7.1M | 0.40% | 174,838 | Common | SOLE |
| 61559X104 | MLTX | MoonLake Immunotherapeutics | $6.9M | 0.38% | 113,757 | Common | SOLE |
| 45784P101 | PODD | Insulet Corp | $4.1M | 0.23% | 19,000 | Common | SOLE |
| 46333X108 | IRWD | Ironwood Pharmaceuticals Inc | $3.8M | 0.21% | 331,099 | Common | SOLE |
| 097702104 | BOLT1EUR | Bolt Biotherapeutics Inc | $3.1M | 0.17% | 2,754,437 | Common | SOLE |
| 65343E108 | NXTCEUR | Nextcure Inc | $3.0M | 0.17% | 2,671,856 | Common | SOLE |
| 252131107 | DXCM | Dexcom Inc | $2.5M | 0.14% | 20,000 | Common | SOLE |
| 216648402 | — | Cooper Cos Inc | $1.5M | 0.08% | 4,000 | Common | SOLE |
| 574795100 | MASI | Masimo Corp | $1.5M | 0.08% | 12,800 | Common | SOLE |
| 67022C106 | — | Nucana PLC | $1.4M | 0.08% | 4,684,120 | Common | SOLE |
| 00847G705 | AGENEUR | Agenus Inc | $1.3M | 0.07% | 1,600,000 | CALL | SOLE |
| 36118A100 | — | Fusion Pharmaceuticals Inc | $1.2M | 0.07% | 125,299 | Common | SOLE |
| 56854Q200 | MRNS* | Marinus Pharmaceuticals Inc | $1.1M | 0.06% | 100,000 | CALL | SOLE |
| N44445117 | IMTXW | Immatics NV | $929,646 | 0.05% | 318,372 | Common | SOLE |
| 45175G108 | — | Ikena Oncology Inc | $716,054 | 0.04% | 363,479 | Common | SOLE |
| GB00BYWYV | — | Nucana PLC | $709,920 | 0.04% | 2,400,000 | Common | SOLE |
| 70465T107 | PDSB | PDS Biotechnology Corp | $708,896 | 0.04% | 142,635 | Common | SOLE |
| 70975L107 | PEN | Penumbra Inc | $503,080 | 0.03% | 2,000 | Common | SOLE |
| 36338D108 | GRTX | Galera Therapeutics Inc | $448,372 | 0.03% | 3,083,712 | Common | SOLE |
| 359616109 | FULC | Fulcrum Therapeutics Inc | $193,050 | 0.01% | 28,600 | Common | SOLE |
| 713317105 | PEPG | PepGen Inc | $156,658 | 0.01% | 23,038 | Common | SOLE |
| G31249108 | ESTA | Establishment Labs Hldgs Inc | $79,016 | 0.00% | 3,052 | Common | SOLE |
| 85209E109 | — | Spruce Biosciences Inc | $66,707 | 0.00% | 22,767 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $48,300 | 0.00% | 1,200 | Common | SOLE |
| 92764N102 | VIR | Vir Biotechnology Inc | $45,220 | 0.00% | 4,495 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.